RO79591B1 - External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns - Google Patents
External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns Download PDFInfo
- Publication number
- RO79591B1 RO79591B1 RO94444A RO9444478A RO79591B1 RO 79591 B1 RO79591 B1 RO 79591B1 RO 94444 A RO94444 A RO 94444A RO 9444478 A RO9444478 A RO 9444478A RO 79591 B1 RO79591 B1 RO 79591B1
- Authority
- RO
- Romania
- Prior art keywords
- wounds
- burns
- mucous membranes
- effects
- external product
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 14
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title claims abstract description 11
- 239000003440 toxic substance Substances 0.000 title abstract description 4
- 230000003472 neutralizing effect Effects 0.000 title description 3
- 231100000167 toxic agent Toxicity 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract description 20
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004327 boric acid Substances 0.000 claims abstract description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims abstract description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002684 aminocaproic acid Drugs 0.000 claims abstract description 4
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 claims abstract description 3
- 231100000331 toxic Toxicity 0.000 claims description 13
- 230000002588 toxic effect Effects 0.000 claims description 13
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 claims description 3
- 239000004133 Sodium thiosulphate Substances 0.000 claims description 3
- 229940113720 aminosalicylate Drugs 0.000 claims description 3
- 229960002534 ephedrine hydrochloride Drugs 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 2
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- MDCWDBMBZLORER-UHFFFAOYSA-N triphenyl borate Chemical compound C=1C=CC=CC=1OB(OC=1C=CC=CC=1)OC1=CC=CC=C1 MDCWDBMBZLORER-UHFFFAOYSA-N 0.000 abstract description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002179 ephedrine Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 8
- 230000000622 irritating effect Effects 0.000 description 7
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 231100000770 Toxic Equivalency Factor Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HHQBTWSCZKUXAR-UHFFFAOYSA-N bis(1,3-dioxa-2-bora-4-mercuracyclobut-2-yloxy)mercury Chemical compound O([Hg]OB1O[Hg]O1)B1O[Hg]O1 HHQBTWSCZKUXAR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- -1 o-chlorobenzylidene Chemical group 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Invenția se referă la un produs extern cu acțiune polivalentă, destinat neutralizării efectelorsubstanțelortoxice de luptă asupra mucoaselor, plăgilor și arsurilor, care, în scopul obținerii unei neutralizări eficiente chimice și farmacodinamice, a substanțelor toxice de luptă, de pe mucoase, plăgi și arsuri, este constituit din lidocaină bază 0,200 g, acid boric 0,4961 g, natrium boracic 1,1464 g, efedrină clorhidrat 3,000 g, tiosulfat aminosalicilat 0,5000 g, acid epsilonaminocaproic 2,000, dextran 70000 în cantitate de 10 g, borat fenil mercuric 0,001...0,004 g în 100 ml apă distilată proaspăt fiartă și răcită.The invention relates to a external product with multipurpose action, intended neutralization of the effects of non-toxic substances fighting mucous membranes, wounds and burns, which, in order to obtain a neutralization chemical and pharmacodynamic efficiencies, of the toxic substances to fight, of on mucous membranes, wounds and burns, it is constituted of lidocaine base 0,200 g, boric acid 0.4961 g, boracic natrium 1.1464 g, ephedrine 3,000 g hydrochloride, aminosalicylated thiosulphate 0.5000 g, epsilonaminocaproic acid 2,000, dextran 70,000 in the amount of 10 g, mercuric phenyl borate 0.001 ... 0.004 g in 100 ml freshly boiled and cooled distilled water.
Description
Invenția de față se referă la un produs extern cu acțiune polivalentă, destinat neutralizării efectelor substanțelor toxice de luptă asupra mucoaselor, plăgilor și arsurilor.The present invention relates to an external product with multipurpose action, intended to neutralize the effects of the toxic control substances on the mucous membranes, wounds and burns.
în scopul neutralizării chimice a substanțelor toxice de luptă care au contaminat mucoasele, plăgile sau arsurile, se cunosc preparate sub formă de soluții, așa cum ar fi: bicarbonat de sodiu 3% pentru substanțele toxice de luptă organofosforice și substanțele toxice de luptă iritante; bicarbonat de sodiu 2%, permanganat de potasiu 0,025....0,05%. monocloramina 0,25...0,50% pentru substanțele toxice de luptă vezicante tip Iperită. Ballantyne B, Gazzard MF, Swanson D.W, Williams P., The ophtalmic toxicology o-chlorobenzylidene malononitrilic (CS) - Arch Toxicol. 32, 149- 168 (1974), Duprat P., Delsaut, Gradiski D, Pouvoir irritant des principaux solvants chlores aliphatiques sur la peau et Ies muqueuses oculaire du lapin, European Journal of Toxicol. 9, nr.3,171 177, (1976).For the purpose of chemical neutralization of toxic control substances which have contaminated mucous membranes, wounds or burns, preparations are known in the form of solutions, such as: 3% sodium bicarbonate for toxic organophosphorus control substances and toxic fighting substances; 2% sodium bicarbonate, potassium permanganate 0.025 .... 0.05%. Monochloramine 0.25 ... 0.50% for toxic hypertensive bladder control substances. Ballantyne B, Gazzard MF, Swanson D.W, Williams P., The ophthalmic toxicology o-chlorobenzylidene malononitrilic (CS) - Arch Toxicol. 32, 149- 168 (1974), Duprat P., Delsaut, Gradiski D, Irritant power of major aliphatic chlorine solvents on skin and rabbit ocular mucosa, European Journal of Toxicol. 9, No.3,171 177, (1976).
Produsul extern cu acțiune polivalentă, destinat neutralizării efectelor substanțelor toxice de luptă asupra mucoaselor plăgilor și arsurilor, conform invenției de față, înlătură dezavantajele arătate, prin aceea că, în scopul obținerii unei acțiuni eficiente și polivalente de neutralizare a substanțelor toxice de luptă, este constituit din lidocaină bază 0,200 g, acid boric 0,4961 g, natrium boracic 1,1464 g, efedrină clorhidrat 3,000 g, tiosulfat de sodiu 5,000 g, feniramin aminosalicilat 0,500 g, acid epsilonaminocaproic 2,000 g dextran 70000 în cantitate de 10,000 g, borat fenil mercuric 0,001...0,004 g, în distilată proaspăt fiartă și răcită, la 100 ml.The external product with multipurpose action, intended to neutralize the effects of the toxic control substances on the mucous membranes of the wounds and burns, according to the present invention, removes the disadvantages shown, in that, in order to obtain an efficient and polyvalent action to neutralize the toxic substances, it is necessary to combat of lidocaine base 0.200 g, boric acid 0.4961 g, boric acid natrium 1.1464 g, ephedrine hydrochloride 3,000 g, sodium thiosulphate 5,000 g, phenosamine aminosalicylate 0.500 g, epsilonaminocaproic acid 2,000 g dextran 70000 in the amount of 10,000 g, phenyl borate mercuric 0.001 ... 0.004 g, in freshly boiled and cooled distillate, to 100 ml.
Se dă, în continuare, un exemplu de realizare a invenției.The following is an example of an embodiment of the invention.
Se iau 80 ml apă distilată, se fierb și se răcesc la 60°C. în această cantitate se dizolvă 0,200 g lidocaină bază prin agitare. Dacă din cauza răcirii soluției, nu s-a dizolvat întreaga cantitate de lidocaină, se adaugă pe rând celelalte componente, în următoarea ordine : acid boric 0,4961 g, natrium boracic 1,1464 g, efedrina clorhidrat 3,000 g, feniramin aminosalicilat 0,500 g, acid epsilonaminocaproic 2,000 g borat fenil mercuric 0,001 ...0,004 g, agitând după fiecare, până la solubilizare completă. După solubilizarea acestor componente, se dizolvă dextranul 70000 prin suspendare în timp de 24 h. După 24 h, soluția incoloră și limpede se transvazează într-un cilindru gradat și se completează cu apă distilată proaspăt fiartă și răcită la volum de 100 ml.Take 80 ml of distilled water, boil and cool to 60 ° C. In this amount, 0.200 g of lidocaine base is dissolved by stirring. If due to cooling of the solution, the whole amount of lidocaine has not been dissolved, the other components are added one by one in the following order: boric acid 0.4961 g, boric acid natrium 1.1464 g, ephedrine hydrochloride 3,000 g, phenosamine aminosalicylate 0.500 g epsilonaminocaproic 2,000 g phenyl mercuric borate 0.001 ... 0.004 g, shaking after each until complete solubilization. After the solubilization of these components, the dextran 70000 is dissolved by suspension for 24 hours. After 24 hours, the colorless and clear solution is transferred to a graduated cylinder and filled with fresh boiled and cooled distilled water to a volume of 100 ml.
Produsul obținut are următoarele caracteristici : lichid limpede, incolor sau cu o tentă ușor gălbuie, cu viscozitate crescută, cu pH = 8,00...8,60, inodor, fără acțiune iritantă și netoxic, steril și cu acțiune autosterilizantă.The product obtained has the following characteristics: clear, colorless or slightly yellowish liquid, with high viscosity, pH = 8.00 ... 8.60, odorless, without irritating and non-toxic action, sterile and with self-sterilizing action.
Din punctul de vedere al acțiunii proprii, preparatul nu are acțiune toxică sau iritantă pe mucoase, tegumente, plăgi sau arsuri experimentale. Preparatul de față este indicat pentru: neutralizarea efectelor substanțelor toxice de luptă (organofosforice, vezicante, iritante) asupra mucoaselor, plăgilor și arsurilor; neutralizarea efectelor insecticidelor organofosforice pe mucoase și plăgi; antagonizarea arsurilor chimice cu acizi ale mucoasei oculare; antagonizarea efectelor iritante ale unor substanțe iritante utilizate de trupele de securitate (în caz de contaminare accidentală a persoanelor care manipulează aceste substanțe); antagonizarea efectelor iritante ale diverselor substanțe cu acțiune iritantă pe mucoasa oculară din industrie. Analizând formula preparatului, se observă că acesta conține un tampon la pH alcalin (acid boric-borax), tampon perfect tolerat de mucoasa oculară; un anestezic sub formă de bază (prin forma de bază acțiune mai pregnantă și în profunzime la nivelul mucoaselor) care, prin blocarea receptorilor, terminațiilor șiFrom the point of view of its own action, the preparation has no toxic or irritating action on mucous membranes, skin, wounds or experimental burns. The present preparation is indicated for: neutralizing the effects of toxic fighting substances (organophosphoric, bladder, irritant) on the mucous membranes, wounds and burns; neutralizing the effects of organophosphorus insecticides on mucous membranes and wounds; antagonizing chemical burns with ocular mucosal acids; antagonizing the irritating effects of some irritating substances used by the security forces (in case of accidental contamination of the persons handling these substances); antagonizing the irritating effects of the various substances with irritating action on the ocular mucosa of the industry. When analyzing the formula of the preparation, it is observed that it contains a buffer at alkaline pH (boric acid-borax), buffer perfectly tolerated by the ocular mucosa; an anesthetic in the basic form (through the basic form more intense and in-depth action on the mucous membranes) which, by blocking the receptors, terminations and
4 fibrelor senzitive, împiedică transmiterea senzațiilor nociceptive (valabil în cazul vezicantelor și iritantelor); un antihistaminic pentru împiedicarea efectelor histaminei eliberate prin agresiunea chimică și care potențează anestezicul local; un simpatomimetic cu efecte mixte alfa și beta, care, pe de o parte, prelungește acțiunea anestezicului local și, pe de altă parte, antagonizează mioza produsă de 10 organofosforice; tiosulfatul de sodiu cu acțiune desensibilizantă, antitoxică și efect direct de neutralizare chimică a Iperitei: acid epsilonaminocaproic cu efecte antialergice, analgezice și antiinflamatoare; o 15 macromoleculă (dextran) cu rol ca prin creșterea viscozității preparatului să prelungească timpul de contact al componentelor preparatului cu țesuturile și borat mercuric, care asigură sterilitatea și 20 conferă rol autosterilizant preparatului.4 sensitive fibers, prevents the transmission of nociceptive sensations (valid in the case of vesicles and irritants); an antihistamine for preventing the effects of histamine released by chemical aggression and potentiating local anesthetic; a sympathomimetic with mixed effects alpha and beta, which, on the one hand, prolongs the action of the local anesthetic and, on the other hand, antagonizes the myosis produced by 10 organophosphorus; sodium thiosulphate with desensitizing, antitoxic action and direct chemical neutralization effect of Hyperitis: epsilonaminocaproic acid with anti-allergic, analgesic and anti-inflammatory effects; o 15 macromolecule (dextran) with the role that by increasing the viscosity of the preparation, it prolongs the contact time of the components of the preparation with the tissues and mercury borate, which ensures sterility and gives the self-sterilizing role to the preparation.
Invenția de față prezintă următoarele avantaje:The present invention has the following advantages:
- posedă o acțiune polivalentă complexă, de antagonizare chimică și 25 farmacodinamică a substanțelor toxice de luptă organofosforice, vezicante și iritante, care au contaminat mucoasele (în special, mucoasa oculară), plăgile și arsurile;- possesses a complex polyvalent action, of chemical antagonization and pharmacodynamics of the toxic organophosphorus, bladder and irritant control substances, which have contaminated the mucous membranes (in particular, the ocular mucosa), the wounds and the burns;
- asigură antagonizarea acțiunii in- 30 secticidelor organofosforice, acțiunii unor substanțe iritante utilizate în industrie și acțiunii unor acizi asupra mucoasei oculare și plăgilor;- ensures the antagonization of the action of the organophosphorus in- secticides, the action of some irritants used in industry and the action of acids on the ocular mucosa and the wounds;
- constituie un produs medicamentos tipizat util, pentru dotarea individuală și colectivă a persoanelor expuse contaminării cu substanțe toxice de luptă sau cu toxice echivalente din industrie și economie;- constitutes a useful typological medicinal product, for the individual and collective endowment of persons exposed to contamination with toxic fighting substances or with toxic equivalent of industry and economy;
- este un preparat stabil, fără acțiune toxică sau iritantă, steril și cu acțiune autosterilizantă;- it is a stable preparation, without toxic or irritating action, sterile and with self-sterilizing action;
- asigură un contact prelungit al substanțelor active cu mucoasele, tegumentele, plăgile și arsurile;- ensures prolonged contact of the active substances with mucous membranes, skin, wounds and burns;
- contribuie alături de alte mijloace antidotice la creșterea eficienței tratamentului intoxicațiilor și la recuperarea lor rapidă.- It contributes, together with other antidotical means, to increase the efficiency of the treatment of poisonings and to their rapid recovery.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO94444A RO79591B1 (en) | 1978-06-23 | 1978-06-23 | External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO94444A RO79591B1 (en) | 1978-06-23 | 1978-06-23 | External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RO79591B1 true RO79591B1 (en) | 2002-06-28 |
Family
ID=40903120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO94444A RO79591B1 (en) | 1978-06-23 | 1978-06-23 | External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns |
Country Status (1)
| Country | Link |
|---|---|
| RO (1) | RO79591B1 (en) |
-
1978
- 1978-06-23 RO RO94444A patent/RO79591B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pişkin et al. | Stability of various sodium hypochlorite solutions | |
| PT88985A (en) | Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine | |
| ES2191048T3 (en) | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOUNDS THAT CONTAIN THEM. | |
| Fisher et al. | Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications | |
| EA200001125A1 (en) | PHARMACEUTICAL PHARMACEUTICAL COMPOSITIONS | |
| ES2076279T3 (en) | DRUGS THAT, AS AN ACTIVE SUBSTANCE, CONTAIN CARBOXYLIC ACIDS WITH SULFUR CONTENT, AS WELL AS THEIR USE TO COMBAT RETROVIRUSES. | |
| RU2128503C1 (en) | Antiviral pharmaceutical emulsion of type "oil-in-water" | |
| FR2391215A1 (en) | NEW IMIDAZOAZINES AND IMIDAZODIAZINES, THEIR PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS | |
| BR0014895A (en) | Liquid stable formulation, process for preparing it, using it, using polyethylene glycol and sodium or potassium salt of an h +, k + -atpase inhibitor, and method to treat gastrointestinal diseases | |
| EP0457805A1 (en) | Biodegradable disinfectant | |
| FR2430408A1 (en) | OPTICALLY ACTIVE PHENETHANOLAMINES AND THEIR THERAPEUTIC USE | |
| FI813912L (en) | I LAEKEMEDEL ANVAENDBARA TRICYCLISKA CYTOSINDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING | |
| FR2598320B1 (en) | WATER-SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING UBIQUINONE AS ACTIVE INGREDIENT USEFUL IN DIFFERENT THERAPEUTIC APPLICATIONS | |
| CO4520283A1 (en) | ANTIVIRAL AGENTS | |
| RU2233151C2 (en) | Application of tosylchloroamides for treatment of skin and mucosa disease | |
| ATE3552T1 (en) | PROCESS FOR THE PREPARATION OF PHOSPHONO-HYDROXY-ACETIC ACID AND SALTS THEREOF AND AUTIVIRALS CONTAINING THEM. | |
| BR0112614A (en) | Compounds, pharmaceutical compositions, use of one or more compounds and process for the manufacture of pharmaceutical compositions | |
| RO79591B1 (en) | External product with polyvalent activity, meant for neutralizing the effects of toxic substance used in combat upon mucous membranes, wounds and burns | |
| DK173716B1 (en) | Non-pharmaceutical composition containing a surfactant and a fluorine compound | |
| Edmundson et al. | Occupational dermatitis from naled: a clinical report | |
| FR2387221A1 (en) | BENZIMIDAZOLE DERIVATIVES FOR USE AS ACTIVE SUBSTANCES IN VETERINARY MEDICINAL PRODUCTS | |
| FR2388562A1 (en) | MEDICINAL PRODUCT CONTAINING 5'-AMINO-5'-DESOXYTHYMIDINE OR A SALT OF THIS SUBSTANCE | |
| RU2175247C1 (en) | Antiseptic composition and method of its preparing | |
| ES497950A0 (en) | PROCEDURE FOR THE PREPARATION OF LIQUID FUNGICIDAL FORMULATIONS | |
| Moore | The causation and prevention of tri-nitro-toluene (TNT) poisoning |